Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

90th European Atherosclerosis Society Congress

22-25 May 2022, Milan, Italy (Hybrid meeting)

Real-world use of PCSK9 inhibitors: latest insights

Real-world use of PCSK9 inhibitors: latest insights

News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy Alirocumab or evolocumab showed a comparable efficacy and safety profile as that reported in clinical trials, according to a meta-analysis of over 28,000 patients prescribed either PCSK9 inhibitor in a real-world clinical…

read more »
EAS FH Studies Collaboration: missed opportunities to identify FH early

EAS FH Studies Collaboration: missed opportunities to identify FH early

News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy Familial hypercholesterolaemia (FH) is characterised by high cholesterol levels from birth, which if untreated confer a risk of accelerated atherosclerotic cardiovascular disease (1). Early identification of children with FH and initiation of…

read more »
Why combination LDL-lowering therapy is mandated by guidelines for very high-risk patients: insights from DA VINCI

Why combination LDL-lowering therapy is mandated by guidelines for very high-risk patients: insights from DA VINCI

News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy According to a simulation study using the DA VINCI data (1), combination LDL-lowering therapy including a PCSK9 inhibitor would result in ~90% of very high-risk patients achieving LDL cholesterol goal, as defined…

read more »
ETESIAN: Phase 2b trial of PCSK9 antisense oligonucleotide

ETESIAN: Phase 2b trial of PCSK9 antisense oligonucleotide

News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy In this study, AZD8233 (ION 449) reduced LDL cholesterol by over 70% on top of statin in patients with dyslipidaemia. The findings follow an initial report at the American College of Cardiology…

read more »